http://www.p3hp.org/20220331#MarkToMarketAdjustmentOfStockWarrants10577504415788900.2541578890415788900001832511--12-312022Q1false41578890415788904300000043000000600000060000001613003416130034http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrentSuccessor196553523197103405SuccessorPredecessor0.251.00http://www.p3hp.org/20220331#MarkToMarketAdjustmentOfStockWarrants84000000840000008400000084000000P3M180000P9M19655352319710340516358331302083P2YP1YP1YP5YP30D0001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-03-310001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2022-03-310001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2022-03-310001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2022-03-310001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2021-12-310001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2021-12-310001832511piii:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2021-12-310001832511piii:ClassCPreferredUnitsMember2020-06-072020-06-070001832511us-gaap:CommonClassAMemberpiii:PrivatePlacementPursuantToSubscriptionAgreementsMember2022-01-012022-03-310001832511us-gaap:RetainedEarningsMember2022-03-310001832511us-gaap:AdditionalPaidInCapitalMember2022-03-310001832511us-gaap:RetainedEarningsMember2021-12-310001832511us-gaap:AdditionalPaidInCapitalMember2021-12-310001832511us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001832511us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001832511us-gaap:FairValueMeasurementsRecurringMember2022-03-310001832511us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001832511us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001832511us-gaap:FairValueMeasurementsRecurringMember2021-12-310001832511us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-03-310001832511piii:CommonClassVMemberus-gaap:CommonStockMember2022-03-310001832511us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001832511piii:CommonClassVMemberus-gaap:CommonStockMember2021-12-310001832511piii:ClassCPreferredUnitsMember2020-06-070001832511piii:CommonClassVMember2021-01-012021-12-310001832511piii:CommonClassVMemberus-gaap:CommonStockMember2022-01-012022-03-310001832511piii:TimeBasedProfitsInterestAwardsMemberpiii:IncentiveAwardPlan2021PlanMember2022-01-012022-03-310001832511piii:TimeBasedProfitsInterestAwardsMemberpiii:IncentiveAwardPlan2021PlanMember2022-03-310001832511piii:TimeBasedProfitsInterestAwardsMemberpiii:IncentiveAwardPlan2021PlanMember2021-12-310001832511srt:MinimumMemberpiii:TimeBasedProfitsInterestAwardsMemberpiii:IncentiveAwardPlan2021PlanMember2022-01-012022-03-310001832511srt:MaximumMemberpiii:TimeBasedProfitsInterestAwardsMemberpiii:IncentiveAwardPlan2021PlanMember2022-01-012022-03-310001832511srt:MinimumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-03-310001832511srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-03-310001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember2022-01-012022-03-310001832511piii:P3LlcMember2022-01-012022-03-310001832511piii:HealthCareClinicalFeesInsuranceRevenueMember2022-01-012022-03-310001832511us-gaap:HealthCarePatientServiceMember2022-01-012022-03-310001832511piii:RevenueAdjustmentsMember2022-01-012022-03-310001832511piii:CapitatedRevenueMember2022-01-012022-03-310001832511us-gaap:HealthCarePatientServiceMembersrt:ScenarioPreviouslyReportedMember2021-01-012021-03-310001832511us-gaap:HealthCarePatientServiceMemberpiii:RevenueAdjustmentsMember2021-01-012021-03-310001832511us-gaap:HealthCarePatientServiceMemberpiii:AsRevisedMember2021-01-012021-03-310001832511piii:CapitatedRevenueMembersrt:ScenarioPreviouslyReportedMember2021-01-012021-03-310001832511piii:CapitatedRevenueMemberpiii:RevenueAdjustmentsMember2021-01-012021-03-310001832511piii:CapitatedRevenueMemberpiii:AsRevisedMember2021-01-012021-03-310001832511us-gaap:HealthCarePatientServiceMember2021-01-012021-03-310001832511piii:CapitatedRevenueMember2021-01-012021-03-310001832511piii:LtdELoanMember2022-01-012022-03-310001832511us-gaap:SoftwareDevelopmentMember2022-03-310001832511us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2022-03-310001832511us-gaap:LeaseholdImprovementsMember2022-03-310001832511us-gaap:FurnitureAndFixturesMember2022-03-310001832511us-gaap:ComputerEquipmentMember2022-03-310001832511piii:MedicalEquipmentMember2022-03-310001832511us-gaap:SoftwareDevelopmentMember2021-12-310001832511us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2021-12-310001832511us-gaap:LeaseholdImprovementsMember2021-12-310001832511us-gaap:FurnitureAndFixturesMember2021-12-310001832511us-gaap:ComputerEquipmentMember2021-12-310001832511piii:MedicalEquipmentMember2021-12-310001832511piii:ClassPreferredUnitsMember2021-03-310001832511piii:ClassDPreferredUnitsMember2021-03-310001832511piii:ClassBPreferredUnitsMember2021-03-310001832511piii:ClassPreferredUnitsMember2020-12-310001832511piii:ClassDPreferredUnitsMember2020-12-310001832511piii:ClassBPreferredUnitsMember2020-12-310001832511piii:ClassCPreferredUnitsMember2021-01-012021-03-310001832511us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-03-310001832511us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-01-012021-03-310001832511us-gaap:RetainedEarningsMember2022-01-012022-03-310001832511us-gaap:RetainedEarningsMember2021-01-012021-03-310001832511piii:NetworkAdjustmentsMember2021-01-012021-03-310001832511piii:P3HealthGroupLlcMember2022-03-310001832511us-gaap:PrimeRateMember2022-03-310001832511piii:P3NvMemberpiii:KahanWakefieldAbdouPllcMember2022-01-012022-03-310001832511piii:P3NvMemberpiii:KahanWakefieldAbdouPllcMember2021-01-012021-12-3100018325112020-03-012022-03-310001832511us-gaap:RetainedEarningsMember2021-03-310001832511srt:ScenarioPreviouslyReportedMember2021-03-310001832511piii:RevenueAdjustmentsMember2021-03-310001832511piii:RedemptionOfProfitsInterestMember2021-03-310001832511piii:PreferredReturnsRestatementAdjustmentMember2021-03-310001832511piii:ClassUnitsAdjustmentsMember2021-03-310001832511piii:ClassCPreferredUnitsMember2021-03-310001832511piii:ClassB1PreferredUnitsMember2021-03-310001832511piii:AsRevisedMember2021-03-310001832511us-gaap:RetainedEarningsMember2020-12-310001832511srt:ScenarioPreviouslyReportedMember2020-12-310001832511piii:RevenueAdjustmentsMember2020-12-310001832511piii:RedemptionOfProfitsInterestMember2020-12-310001832511piii:PreferredReturnsRestatementAdjustmentMember2020-12-310001832511piii:ClassUnitsAdjustmentsMember2020-12-310001832511piii:ClassCPreferredUnitsMember2020-12-310001832511piii:ClassB1PreferredUnitsMember2020-12-310001832511piii:AsRevisedMember2020-12-310001832511srt:MinimumMemberpiii:EquipmentOnLeaseMember2022-03-310001832511srt:MaximumMemberpiii:EquipmentOnLeaseMember2022-03-310001832511srt:MinimumMemberus-gaap:RealEstateMember2022-03-310001832511srt:MaximumMemberus-gaap:RealEstateMember2022-03-310001832511us-gaap:TransmissionServiceAgreementMember2022-03-310001832511us-gaap:TrademarksMember2022-03-310001832511us-gaap:LicensingAgreementsMember2022-03-310001832511us-gaap:CustomerRelationshipsMember2022-03-310001832511piii:ProviderContractsMember2022-03-310001832511us-gaap:TransmissionServiceAgreementMember2021-12-310001832511us-gaap:TrademarksMember2021-12-310001832511us-gaap:LicensingAgreementsMember2021-12-310001832511us-gaap:CustomerRelationshipsMember2021-12-310001832511piii:ProviderContractsMember2021-12-310001832511us-gaap:SubsequentEventMember2022-04-012022-06-3000018325112022-04-012022-06-3000018325112021-12-312021-12-310001832511piii:PrivatePlacementWarrantsMember2022-03-310001832511piii:PrivatePlacementWarrantsMember2021-12-310001832511piii:PrivatePlacementWarrantsMember2021-03-310001832511piii:PrivatePlacementWarrantsMember2020-12-310001832511piii:PrivatePlacementWarrantsMember2022-01-012022-03-310001832511piii:PrivatePlacementWarrantsMember2021-01-012021-03-310001832511us-gaap:CommonClassAMember2021-01-012021-03-310001832511piii:ClassDWarrantsMember2020-01-012020-12-310001832511us-gaap:LineOfCreditMember2021-12-310001832511srt:MinimumMemberus-gaap:LineOfCreditMember2021-01-012021-12-310001832511srt:MaximumMemberus-gaap:LineOfCreditMember2021-01-012021-12-310001832511piii:LtdCLoanMember2020-11-190001832511piii:LtdELoanMember2020-06-070001832511piii:LtdDLoanMember2020-11-190001832511piii:LtdELoanMember2022-03-310001832511piii:LtdELoanMember2021-12-310001832511piii:ClassBForesightFounderSharesMember2022-01-012022-03-310001832511us-gaap:HealthCarePatientServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001832511piii:HealthPlanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001832511piii:HealthPlanDMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001832511piii:HealthPlanCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001832511piii:HealthPlanBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001832511piii:HealthCareIncentiveFeesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001832511piii:HealthCareClinicalFeesInsuranceRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001832511piii:HealthCareCareCoordinationManagementFeesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001832511piii:CapitatedRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001832511piii:AllOtherHealthPlanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001832511us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001832511us-gaap:HealthCarePatientServiceMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001832511piii:HealthPlanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001832511piii:HealthPlanDMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001832511piii:HealthPlanCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001832511piii:HealthPlanBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001832511piii:HealthCareIncentiveFeesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001832511piii:HealthCareClinicalFeesInsuranceRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001832511piii:HealthCareCareCoordinationManagementFeesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001832511piii:CapitatedRevenueMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001832511piii:AllOtherHealthPlanMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001832511us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001832511piii:ChiefExecutiveOfficerAndChiefMedicalOfficerMemberus-gaap:SubsequentEventMember2022-05-132022-05-130001832511piii:P3LlcMemberus-gaap:RestrictedStockMember2022-03-310001832511us-gaap:NoncontrollingInterestMember2022-03-310001832511piii:P3LlcMember2022-03-310001832511piii:P3LlcMemberus-gaap:RestrictedStockMember2021-12-310001832511us-gaap:NoncontrollingInterestMember2021-12-310001832511piii:P3LlcMember2021-12-310001832511piii:CommonClassVMember2022-03-310001832511piii:CommonClassVMember2021-12-310001832511piii:ClassDWarrantsMember2022-03-310001832511us-gaap:CommonClassAMember2021-12-310001832511piii:ClassDWarrantsMember2020-12-310001832511piii:LtdDLoanMemberus-gaap:SeriesDPreferredStockMember2022-03-310001832511us-gaap:CommonClassAMember2022-03-310001832511piii:ClassDWarrantsMember2021-12-310001832511piii:ClassDWarrantsMember2020-11-1900018325112021-03-310001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMemberus-gaap:TransmissionServiceAgreementMember2021-12-310001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMemberus-gaap:TrademarksMember2021-12-310001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMemberus-gaap:LicensingAgreementsMember2021-12-310001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMemberus-gaap:ContractualRightsMember2021-12-310001832511piii:P3LlcMemberus-gaap:TransmissionServiceAgreementMember2021-12-030001832511piii:P3LlcMemberus-gaap:TrademarksMember2021-12-030001832511piii:P3LlcMemberus-gaap:CustomerRelationshipsMember2021-12-030001832511us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:CustomerRelationshipsMember2021-03-310001832511piii:OmniIpaMedicalGroupInc.Member2021-12-310001832511piii:MedcoreHpMember2021-12-270001832511piii:P3HealthGroupLlcMember2021-12-030001832511piii:P3LlcMember2021-01-010001832511us-gaap:RestrictedStockMember2022-01-012022-03-310001832511us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001832511piii:PublicWarrantsMember2022-01-012022-03-310001832511piii:PrivateWarrantsMember2022-01-012022-03-310001832511piii:CommonClassVMember2022-01-012022-03-310001832511us-gaap:TransmissionServiceAgreementMember2022-01-012022-03-310001832511us-gaap:TrademarksMember2022-01-012022-03-310001832511us-gaap:CustomerRelationshipsMember2022-01-012022-03-310001832511piii:ProviderContractsMember2022-01-012022-03-310001832511us-gaap:PerformanceSharesMember2022-01-012022-03-310001832511us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001832511piii:P3LlcMember2021-01-012021-01-010001832511us-gaap:CommonClassAMember2021-01-012021-12-310001832511piii:ClassDWarrantsMember2021-01-012021-12-310001832511us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001832511piii:P3LlcMemberpiii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember2022-03-310001832511us-gaap:LineOfCreditMember2022-03-3100018325112020-12-310001832511piii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember2022-01-012022-03-310001832511piii:LtdDLoanMember2022-01-012022-03-310001832511piii:HealthCareSharedRiskRevenueMember2022-01-012022-03-310001832511piii:ClassCPreferredUnitsMember2020-11-190001832511srt:MinimumMemberus-gaap:RealEstateMember2022-01-012022-03-310001832511srt:MaximumMemberus-gaap:RealEstateMember2022-01-012022-03-3100018325112021-01-012021-12-310001832511piii:RevenueAdjustmentsMember2021-01-012021-03-310001832511piii:AsRevisedMember2021-01-012021-03-310001832511piii:AtrioMember2022-01-012022-03-310001832511srt:ScenarioPreviouslyReportedMember2021-01-012021-03-310001832511piii:PreferredReturnsRestatementAdjustmentMember2021-01-012021-03-310001832511piii:RenegotiationOfAgreementOfHealthPlanDueToDiscrepancyMember2021-10-012021-12-310001832511piii:HealthPlanVMember2022-03-310001832511piii:HealthPlanUMember2022-03-310001832511piii:HealthPlanOMember2022-03-310001832511piii:HealthPlanMember2022-03-310001832511piii:HealthPlanIMember2022-03-310001832511piii:HealthPlanGMember2022-03-310001832511piii:HealthPlanFMember2022-03-310001832511piii:HealthPlanBMember2022-03-310001832511piii:HealthPlanVMember2021-12-310001832511piii:HealthPlanUMember2021-12-310001832511piii:HealthPlanOMember2021-12-310001832511piii:HealthPlanIMember2021-12-310001832511piii:HealthPlanGMember2021-12-310001832511piii:HealthPlanFMember2021-12-310001832511piii:HealthPlanDMember2021-12-310001832511piii:HealthPlanBMember2021-12-310001832511piii:HealthPlanUMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanTMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanSMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanRMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanQMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanPMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanOMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanNMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanMMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanLMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanKMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanJMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanIMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanHMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanGMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanFMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanEMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanDMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanCMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanBMemberpiii:CapitatedRevenueMember2022-03-310001832511piii:CapitatedRevenueMember2022-03-310001832511piii:HealthPlanUMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanTMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanRMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanQMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanPMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanOMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanNMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanMMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanLMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanKMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanJMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanIMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanHMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanGMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanFMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanEMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanDMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanCMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:HealthPlanBMemberpiii:CapitatedRevenueMember2021-12-310001832511piii:CapitatedRevenueMember2021-12-310001832511srt:MinimumMember2022-03-310001832511srt:MaximumMember2022-03-310001832511piii:P3LlcMemberpiii:TaxReceivableAgreementWithSellingEquityHoldersOfP3LlcMember2022-01-012022-03-310001832511piii:LtdCLoanMember2020-11-192020-11-190001832511piii:LtdDLoanMember2025-01-012025-12-310001832511piii:LtdDLoanMember2024-01-012024-12-310001832511piii:LtdDLoanMember2023-01-012023-12-310001832511piii:LtdDLoanMember2022-01-012022-12-310001832511piii:LtdDLoanMember2021-01-012021-12-310001832511piii:LtdDLoanMember2022-03-310001832511piii:LtdCLoanMember2022-03-310001832511piii:LtdDLoanMember2021-12-310001832511piii:LtdCLoanMember2021-12-310001832511piii:LtdDLoanMember2020-11-092020-11-090001832511us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-03-310001832511us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-12-310001832511piii:ClassDWarrantsMember2020-11-192020-11-1900018325112022-03-3100018325112021-12-310001832511piii:CommonClassVMember2022-01-012022-03-310001832511us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-03-310001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember2021-12-310001832511piii:P3LlcMember2021-12-030001832511piii:MedcoreHealthPlanIncAndOmniIpaMedicalGroupIncMember2021-12-272021-12-310001832511us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-01-012021-03-3100018325112021-01-012021-03-310001832511piii:P3LlcMember2021-12-032021-12-030001832511piii:LtdELoanMemberpiii:ClassCPreferredUnitsMember2020-06-072020-06-070001832511us-gaap:CommonClassAMember2022-01-012022-03-310001832511piii:WarrantsExercisableForOneShareOfCommonStockMember2022-01-012022-03-310001832511us-gaap:CommonClassAMember2022-10-140001832511piii:CommonClassVMember2022-10-1400018325112022-01-012022-03-31piii:Optionpiii:shareholderpiii:statepiii:paymentpiii:Yxbrli:sharesiso4217:USDpiii:itemiso4217:USDxbrli:sharespiii:Dpiii:Votexbrli:purepiii:planpiii:lease

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to

Commission file number: 001-40033

P3 Health Partners Inc.

(Exact name of registrant as specified in its charter)

Delaware

85-2992794

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

2370 Corporate Circle Suite 300 Henderson, Nevada

89074

(Address of principal executive offices)

(Zip code)

(702) 910-3950

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Name of each exchange

Title of each class

Trading Symbol(s)

on which registered

Class A Common Stock, Par Value $0.0001 per share Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50

PIII

PIIIW

The Nasdaq Stock Market LLC

The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer 

Smaller reporting company 

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of outstanding shares of the Registrant’s Class A Common Stock, par value $0.0001 as of October 14, 2022, was 41,578,890. The number of outstanding shares of the Registrant’s Class V Common Stock, par value $0.0001 as of October 14, 2022, was 202,024,923.

Table of Contents

TABLE OF CONTENTS

Page

Cautionary Statement Regarding Forward-Looking Statements

PART I – FINANCIAL INFORMATION

Item 1.

Financial Statements

1

Condensed Consolidated Balance Sheets

1

Condensed Consolidated Statements of Operations

2

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) and Mezzanine Equity

3

Condensed Consolidated Statements of Cash Flows

4

Notes to Unaudited Condensed Consolidated Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

35

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

49

Item 4.

Controls and Procedures

49

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

51

Item 1A.

Risk Factors

51

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

51

Item 3.

Defaults Upon Senior Securities

51

Item 4.

Mine Safety Disclosures

51

Item 5.

Other Information

51

Item 6.

Exhibits

51

SIGNATURES

Table of Contents

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

In addition to historical information, this Quarterly Report on Form 10-Q (this “Form 10-Q”) for the quarterly period ended March 31, 2022, may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections. All statements other than statements of historical facts contained in this Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, future revenue, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products and prospects, plans and objectives of management, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “would” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Form 10-Q and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this Form 10-Q entitled “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Form 10-Q. These forward-looking statements are subject to numerous risks, including, without limitation, the following:

our management has performed an analysis of our ability to preserve an adequate level of liquidity for a period extending twelve months and has identified substantial doubt about our ability to continue as a going concern. As a result of this analysis, we may look to add additional capital or may delay or scale back growth as needed, to generate liquidity and positive cash flow as soon as possible;
our ability to recognize the anticipated benefits of the Business Combinations (as defined below), which may be affected by, among other things, competition and our ability to grow and manage growth profitably following the Business Combinations;
changes in applicable laws or regulations;
the possibility that we may be adversely affected by other economic, business, and/or competitive factors, including economic instability and inflationary conditions;
the possibility that we may never achieve or maintain profitability;
the difficulty in evaluating our future prospects, as well as risks and challenges, due to the new and rapidly evolving business and market and our limited operating history;
the possibility that we may need to raise additional capital to fund our existing operations, develop and commercialize new services or expand our operations;
possible difficulty managing growth and expanding operations;
the continuing impact of the COVID-19 pandemic on operations, which may materially and adversely affect our business and financial results;
our ability to retain qualified personnel;
our ability to successfully execute on growth strategies, including identifying and developing successful new geographies, physician partners, payors and patients, and accurately estimating the size, revenue or medical expense amounts of target geographies;
delays and uncertainties in the timing and process of reimbursements by third-party payors and individuals, including any changes or reductions in Medicare reimbursement rates or rules;

Table of Contents

the termination or non-renewal of the Medicare Advantage contracts held by the health plans with which we contract, or the termination or non-renewal of our contracts with those plans;
reductions in the quality ratings of the health plans we serve;
the effectiveness and efficiency of our marketing efforts, and our ability to develop brand awareness cost-effectively;
spending changes in the healthcare industry;
we, our affiliated professional entities and other physician partners may become subject to medical liability claims;
a failure in our information technology systems;
security breaches, loss of data or other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information, expose us to liability and our reputation may be harmed and we could lose revenue, clients and members;
any future litigation against us could be costly and time-consuming to defend;
failure to adhere to all of the complex government laws and regulations that apply to our business could result in fines or penalties, being required to make changes to our operations or experiencing adverse publicity;
failure to establish and maintain effective internal control over financial reporting and remediate identified material weaknesses;
failure to comply with the continued listing standards of Nasdaq;
the possibility that our arrangements with affiliated professional entities and other physician partners is found to constitute improper rendering of medical services or fee splitting under applicable state laws;
the possibility that we face inspections, reviews, audits and investigations under federal and state government programs and contracts;
the impact on us of recent healthcare legislation and other changes in the healthcare industry and in healthcare spending is currently unknown;
the transition from volume to value-based reimbursement models may have a material adverse effect on our operations;
the risks and uncertainties identified in Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the Form 10-Q; and
the risks and uncertainties described under Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”).

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

You should read this Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

Table of Contents

PART IFINANCIAL INFORMATION

Item 1.Financial Statements

P3 HEALTH PARTNERS INC and SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

Successor

    

As of March 31, 2022

    

As of December 31, 2021

ASSETS

CURRENT ASSETS:

Cash

$

110,345,801

$

140,477,586

Restricted Cash

 

356,242

 

356,286

Health Plan Receivables

 

94,587,702

 

50,251,004

Clinic Fees and Insurance Receivables, Net

 

767,396

 

1,090,104

Other Receivables

 

587,833

 

726,903

Prepaid Expenses and Other Current Assets

 

6,743,525

 

6,959,067

TOTAL CURRENT ASSETS

 

213,388,499

 

199,860,950

LONG-TERM ASSETS:

 

  

 

  

Property and Equipment

 

9,085,895

 

8,230,250

Less: Accumulated Depreciation

 

(757,158)

 

(182,321)

Property and Equipment, Net

 

8,328,737

 

8,047,929

Goodwill

 

1,309,750,216

 

1,309,750,216

Intangible Assets, Net

 

814,677,323

 

835,838,605

Notes Receivable, Net

 

3,561,508

 

3,590,715

Right of Use Asset

 

6,933,928

 

7,020,045

TOTAL LONG-TERM ASSETS

 

2,143,251,712

 

2,164,247,510

TOTAL ASSETS (1)

$

2,356,640,211

$

2,364,108,460

LIABILITIES, MEZZANINE EQUITY and STOCKHOLDERS’ EQUITY

 

  

 

  

CURRENT LIABILITIES:

 

  

 

  

Accounts Payable and Accrued Expenses

$

21,726,910

$

17,730,683

Accrued Payroll

 

7,686,205

 

6,304,362

Health Plans Settlements Payable

 

18,640,013

 

22,548,694

Claims Payable

 

137,407,952

 

101,958,324

Premium Deficiency Reserve

 

36,511,129

 

37,835,642

Accrued Interest

 

10,011,573

 

8,771,065

Current Portion of Long-Term Debt

 

23,144

 

46,101

Short-Term Debt

 

2,394,079

 

3,578,561

TOTAL CURRENT LIABILITIES

 

234,401,005

 

198,773,432

LONG-TERM LIABILITIES:

 

  

 

  

Right of Use Liability

 

6,327,733

 

6,296,883

Warrant Liabilities

 

17,244,101

 

11,382,826

Contingent Consideration

 

3,577,417

 

3,486,593

Long-Term Debt

 

80,000,000

 

80,000,000

TOTAL LONG-TERM LIABILITIES

 

107,149,251

 

101,166,302

TOTAL LIABILITIES (1)

 

341,550,256

 

299,939,734

COMMITMENTS AND CONTINGENCIES (NOTE 23)

 

  

 

  

MEZZANINE EQUITY

 

  

 

  

Redeemable Non-Controlling Interest

 

1,752,115,963

 

1,790,617,285

STOCKHOLDERS’ EQUITY:

 

  

 

  

Class A Common Stock, $.0001 par value; 800,000,000 shares authorized; 41,578,890 shares issued and outstanding as of March 31, 2022, and December 31, 2021, respectively

 

4,158

 

4,158

Class V Common Stock, $.0001 par value; 205,000,000 shares authorized; 197,103,405 shares and 196,553,523 shares issued and outstanding as of March 31, 2022, and December 31, 2021, respectively

 

19,710

 

19,655

Additional Paid in Capital

 

312,945,752

 

312,945,752

Accumulated Deficit

 

(49,995,628)

 

(39,418,124)

TOTAL STOCKHOLDERS’ EQUITY

 

262,973,992

 

273,551,441

TOTAL LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS’ EQUITY

$

2,356,640,211

$

2,364,108,460

(1)The Company's condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). As discussed in Note 25: Variable Interest Entities, P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and numbers below refer only to VIEs held at the P3 LLC level. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of P3 LLC's VIEs totaling $9.2 million and $8.1 million as of March 31, 2022, and December 31, 2021, respectively, and total liabilities of the P3 LLC's consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled $7.8 million and $6.1 million as of March 31, 2022, and December 31, 2021, respectively. These VIE assets and liabilities do not include $6.0 million of investment in affiliates as of March 31, 2022, and December 31, 2021, and $25.5 million and $24.1 million of amounts due to affiliates as of March 31, 2022, and December 31, 2021, respectively, as these are eliminated in consolidation and not presented within the condensed consolidated balance sheets. See Note 25 "Variable Interest Entities."

See accompanying notes to condensed consolidated financial statements.

1

Table of Contents

P3 HEALTH PARTNERS INC and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

    

Successor

  

  

Predecessor

Three Months Ended

Three Months Ended

March 31, 2022

March 31, 2021

(As Restated)

OPERATING REVENUE:

Capitated Revenue

$

269,684,815

$

148,964,190

Other Patient Service Revenue

 

3,859,519

 

2,333,750

TOTAL OPERATING REVENUE

 

273,544,334

 

151,297,940

OPERATING EXPENSES:

 

  

 

  

Medical Expenses

 

265,820,802

 

146,624,505

Premium Deficiency Reserve

 

(1,324,513)

 

2,000,000

Corporate, General and Administrative Expenses

 

38,599,412

 

15,059,076

Sales and Marketing Expenses

 

864,530

 

270,241

Amortization of Intangibles

21,161,282

Depreciation

 

590,549

 

332,548

TOTAL OPERATING EXPENSES

 

325,712,062

 

164,286,370

OPERATING LOSS

 

(52,167,728)

 

(12,988,430)

OTHER INCOME (EXPENSES):

 

  

 

  

Interest Expense, net

 

(2,761,250)

 

(2,124,286)

Mark-to-Market of Stock Warrants

 

(5,861,276)

 

(9,537,996)

TOTAL OTHER INCOME (EXPENSE)

 

(8,622,526)

 

(11,662,282)

LOSS BEFORE INCOME TAXES

 

(60,790,254)

 

(24,650,712)

PROVISION FOR INCOME TAXES

 

 

NET LOSS

(60,790,254)

(24,650,712)

LESS NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTERESTS

 

(50,212,750)

 

NET LOSS ATTRIBUTABLE TO CONTROLLING INTERESTS

$

(10,577,504)

$

(24,650,712)

NET LOSS PER SHARE (BASIC AND DILUTED)

$

(0.25)

 

N/A1

See accompanying notes to condensed consolidated financial statements.

2

Table of Contents

P3 HEALTH PARTNERS INC and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’/MEMBERS’ EQUITY (DEFICIT) AND MEZZANINE EQUITY

(UNAUDITED)

Predecessor

Class A

Class D

Class B1

Class C

Redemption of

Accumulated

Total Members’

    

Units

    

Amount

    

Units

    

Amount

  

  

Units

    

Amount

    

Units

    

Amount

    

Profit Interest

    

Deficit

    

Deficit

MEMBERS' DEFICIT, DECEMBER 31, 2020 As Restated

 

43,000,000

$

43,656,270

16,130,034

$

47,041,554

6,000,000

$

380,000

 

1,302,083

$

67,474

$

(180,000)

$

(130,485,179)

$

(130,217,705)

Class C Unit Based Compensation

 

 

 

 

333,750

 

460,515

 

 

 

460,515

Net Loss

 

 

 

 

 

 

 

(24,650,712)

 

(24,650,712)

MEMBERS’ DEFICIT, MARCH 31, 2021 As Restated

 

43,000,000

$

43,656,270

16,130,034

$

47,041,554

6,000,000

$

380,000

 

1,635,833

$

527,989

$

(180,000)

$

(155,135,891)

$

(154,407,902)

Successor

Additional Paid in

Redeemable Noncontrolling

Class A Common Stock

Class V Common Stock

Capital

Accumulated Deficit

Total Stockholders’ Equity

    

Interests

  

  

Shares

    

Amount

    

Shares

    

Amount

    

Amount

    

Amount

    

Amount

STOCKHOLDERS’ EQUITY (DEFICIT), December 31, 2021

$

1,790,617,285

41,578,890

$

4,158

196,553,523

$

19,655

$

312,945,752

$

(39,418,124)

$

273,551,441

Vesting of stock compensation awards

549,822

55

55

Stock compensation

 

11,711,428

 

 

 

 

 

 

 

Net Loss

 

(50,212,750)

 

 

 

 

 

 

(10,577,504)

 

(10,577,504)

STOCKHOLDERS’ EQUITY (DEFICIT), March 31, 2022

$

1,752,115,963

 

41,578,890

$

4,158

 

197,103,345

$

19,710

$

312,945,752

$

(49,995,628)

$

262,973,992

See Accompanying Notes to Condensed Consolidated Financial Statements

3

Table of Contents

P3 HEALTH PARTNERS INC and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

    

Successor

  

  

Predecessor

Three Months Ended

Three Months Ended

March 31, 2022

March 31, 2021

(As Restated)

Cash Flows from Operating Activities

Net Loss

$

(60,790,254)

$

(24,650,712)

Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:

 

  

 

  

Depreciation Expense

 

590,549

 

332,548

Amortization of Intangibles

21,161,282

Stock-Based Compensation

 

11,711,428

 

460,515

Amortization of Discount from Issuance of Debt

 

 

310,653

Mark-to-Market Adjustment of Stock Warrants

 

5,861,276

 

9,537,996

Amortization of Debt Origination Fees

 

 

171,936

Premium Deficiency Reserve

 

(1,324,513)

 

2,000,000

Non-Cash Interest Expense

90,824

Changes in Assets and Liabilities:

 

  

 

  

Accounts Receivable

 

805,178

 

(46,822)

Health Plan Receivables / Premiums

 

(44,336,698)

 

(8,235,713)

Other Current Assets

 

215,542

 

(5,931)

Net Change in ROU Assets and Liabilities

58,423

9,014

Accounts Payable

 

4,018,630

 

85,555

Accrued Payroll

 

1,381,843

 

710,148

Accrued Interest

 

1,240,508

 

874,850

Health Plan Payables / Premiums

 

(3,908,681)

 

1,988,897

Claims Payable

 

35,449,628

 

3,335,346

Net Cash used in Operating Activities

 

(27,775,035)

 

(13,121,720)

Cash Flows from Investing activities

 

  

 

  

Purchase of Property and Equipment

 

(877,165)

 

(656,177)

Increase in Notes Receivable, Net

 

(272,190)

 

(73,495)

Net Cash used in Investing Activities

 

(1,149,355)

 

(729,672)

Cash Flows from Financing activities

 

  

 

  

Repayment of Short-Term and Long-Term Debt

 

(1,207,439)

 

(22,224)

Net Cash used in Financing Activities

 

(1,207,439)

 

(22,224)

Net Change in Cash and Restricted Cash

 

(30,131,829)

 

(13,873,616)

Cash and Restricted Cash, Beginning of Period

 

140,833,872

 

39,902,947

Cash and Restricted Cash, End of Period

$

110,702,043

$

26,029,331

See accompanying notes to condensed consolidated financial statements.

4

Table of Contents

P3 HEALTH PARTNERS INC and SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1: Organization and Basis of Presentation

Description of Business and Business Combination

P3 Health Partners Inc. (the “Company” or “P3”) is a patient-centered and physician-led population health management company and the successor to P3 Health Group Holdings, LLC

P3 Health Group Holdings, LLC and Subsidiaries was founded on April 12, 2017, and began commercial operations on April 20, 2017, to provide population health management services on an at-risk basis to insurance plans offering medical coverage to Medicare beneficiaries under Medicare Advantage programs. Medicare Advantage programs are insurance products created solely for Medicare beneficiaries. Insurance plans contract directly with the Centers for Medicare and Medicaid Services (“CMS”) to offer Medicare beneficiaries benefits that replace traditional Medicare Fee for Service (“FFS”) coverage.

On December 3, 2021, (the “Closing Date”), the Company consummated the transactions pursuant to which, among other things, P3 Health Group Holdings, LLC merged with and into FAC Merger Sub LLC, a Delaware limited liability company and wholly owned subsidiary of Foresight Acquisition Corp. (“Foresight” or “Merger Sub”) (the “P3 Merger”), with Merger Sub as the surviving company, which was renamed P3 Health Group, LLC (“P3 LLC”), and FAC-A Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Foresight, FAC-B Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Foresight (together with FAC-A Merger Sub Corp., the “Merger Corps”) merged with and into CPF P3 Blocker-A, LLC, a Delaware limited liability company, CPF P3 Blocker-B, LLC a Delaware limited liability company (together with CPF P3 Blocker-A, LLC, the “Blockers”), with the Blockers as the surviving entities and wholly-owned subsidiaries of Foresight (collectively, the “Business Combinations”). Upon completion of the Business Combinations (the “Closing”), the Company and P3 LLC were organized in an “Up-C” structure in which all of the P3 LLC operating subsidiaries are held directly or indirectly by P3 LLC, and the Company directly owned approximately 17.1% of P3 LLC and became the sole manager of P3 LLC. Following Closing, substantially all of the Company’s assets and operations are held and conducted by P3 LLC and its subsidiaries, and the Company’s only assets are equity interest in P3 LLC. In connection with the closing of the transactions, the Company changed its name from Foresight Acquisition Corp. to P3 Health Partners Inc.

The Company’s contracts with health plans are based on an at-risk shared savings model. Under this model, the Company is financially responsible for the cost of all contractually covered services provided to members assigned to the Company by health plans in exchange for a fixed monthly “capitation” payment, which is generally a percentage of the payment health plans receive from CMS. Under this arrangement, Medicare beneficiaries generally receive all their healthcare coverage through the Company’s network of employed and affiliated physicians and specialists (except for emergency situations).

The services provided to health plans’ members vary by contract. These may include utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. Effective January 1, 2019, the Company is also responsible for the credentialing of Company providers, processing and payment of claims and the establishment of a provider network for certain health plans. At March 31, 2022, and December 31, 2021, the Company had agreements with twenty and seventeen health plans, respectively.

The Company has Management Services Agreements (“MSAs”) and deficit funding agreements with Kahan, Wakefield, Abdou, PLLC and Bacchus, Wakefield, Kahan, PC, P3 Health Partners Professional Services P.C., P3 Medical Group, P.C. and P3 Health Partners California, P.C. (collectively, the “Network”). As more fully described in Note 25 “Variable Interest Entities”, the entities in the Network are variable interest entities and the Company is the primary beneficiary of the Network. The MSAs provide that the Company or its subsidiaries will furnish administrative personnel, office supplies and equipment, general business services, contract negotiation and billing and collection services to the Network. Fees for these services are the excess of the Network’s revenue over expenses. Per the deficit funding agreements, the Company or its subsidiaries are obligated to lend amounts to the Network to the extent expenses exceed revenues. The loan will bear interest at prime plus 2%.

In addition to the Company’s contracts with health plans, through its relationship with Kahan, Wakefield, Abdou, PLLC and Bacchus, Wakefield, Kahan, PC, the Company provides primary healthcare services through its employed physician clinic locations. These primary care clinics are reimbursed for services provided under FFS contracts with various payers and through capitated – per member, per month (“PMPM”) arrangements.

5

Table of Contents

Basis of Presentation

These unaudited interim condensed consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of the U.S. Securities and Exchange Commission (“SEC”) Regulation S-X. The condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in our 2021 Form 10-K for the year ended December 31, 2021 (“2021 Form 10-K”). Certain information and footnote disclosures, normally included in financial statements prepared in accordance with U.S. GAAP, have been condensed or omitted pursuant to SEC rules and regulations dealing with interim financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the periods presented. Operating results for the three months ended March 31, 2022, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022. For further information, refer to the consolidated financial statements and notes thereto included in our 2021 Form 10-K. There have been no significant changes to our accounting policies and estimates during the three months ended March 31, 2022, from those previously disclosed in the 2021 Form 10-K.

As a result of the Business Combinations, for accounting purposes, Foresight is the acquirer and P3 Health Group Holdings, LLC is the accounting acquiree and predecessor. The financial statement presentation includes the financial statements of P3 Health Group Holdings, LLC as “Predecessor” for the periods prior to the Closing Date (the “Predecessor Period(s)”) and of the Company as “Successor” for the periods after the Closing Date (the “Successor Period(s)”), including the consolidation of P3 Health Group Holdings, LLC.

As a result of the application of the acquisition method of accounting as of the Closing Date of the Business Combinations, the accompanying unaudited condensed consolidated financial statements include a black line division that indicates that the Predecessor and Successor reporting entities shown are presented on a different basis and are therefore, not comparable.

The Company qualifies as an Emerging Growth Company (“EGC”) and as such, has elected the extended transition period for complying with certain new or revised accounting pronouncements. During the extended transition period, the Company is not subject to certain new or revised accounting standards applicable to public companies. The accounting pronouncements pending adoption as described in Note 6 “Recent Accounting Pronouncements Not Yet Adopted” reflect effective dates for the Company as an EGC with the extended transition period.

Restatement of Prior Year Amounts

As discussed in the Company’s 2021 consolidated financial statements included in the 2021 Form 10-K, the Company restated the previously issued unaudited condensed consolidated financial statements for each interim period within the fiscal years ended December 31, 2021, and December 31, 2020.

Note 2: Restatement of Previously Issued Financial Statements

The Company has restated the condensed consolidated financial statements for the three months ended March 31, 2021.

Network

Since 2017, P3 Health Group Holdings and P3 Health Partners, LLC (collectively with P3 Health Partners, Inc., "P3") have entered into a collective of arrangements with the Network whereby P3 consolidates the Network under the Variable Interest Entity model in accordance with ASC Topic 810, Consolidation (“ASC 810”). Historically, all of the net losses incurred by the Network has been allocated to loss attributable to non-controlling interests. Based on an analysis of the deficit funding agreement between P3 and the Network, P3 is obligated to fund losses incurred by the Network. Because P3 is contractually obligated to fund the losses, losses incurred by the Network should not be allocated to non-controlling interests.

Based on management’s evaluation, it was concluded that the Company’s accounting for non-controlling interests related to the Network is not attributed in the manner contemplated by ASC 810. As a result, the Company is reclassifying the loss attributable to non-controlling interest related to the Network to loss attributable to controlling interests on the Consolidated Balance Sheets, Consolidated Statements of Operations, and the Consolidated Statements of Changes in Stockholders’/Members’ Equity for the periods described above.

6

Table of Contents

The Company's accounting for the loss in controlling interests instead of non-controlling interests has no impact on the Company's current or previously reported cash position, revenue, operating expenses or total operating, investing or financing cash flows.

Preferred Returns

P3's capital structure consists of Class A Units, which represent commitments from the Company’s private equity sponsors, and Class D Units, which represents an additional investment from a private equity sponsor. Both the Class A and Class D Units have voting rights and, accrue a preferred return in the amount of 8.0% per annum.

Historically, all of the accrued returns have been incorrectly recognized as interest expense on P3’s Statements of Operations and as equity on P3’s Balance Sheets. Based on the analysis of the Class A and Class D Units, the preferred returns should not be accrued until they are legally declared. As a result, the Company’s historical recording of preferred returns in equity and interest expense has been removed as no recognition is necessary until legally declared.  

Class A Units

Historically, the Class A Preferred Units issued by P3 have been accounted for as permanent equity. Since the Class A Preferred Units are redeemable upon the occurrence of a Sale of the Company via the liquidation and distribution preferences that returns invested capital and the preferred return, management evaluated whether the occurrence of such an event is outside of the Company’s control. As the Class A preferred unit holders hold a majority vote, the redemption of Class A Preferred Units upon a Sale of the Company, irrespective of probability, is outside of the Company’s control.

Based on management’s evaluation, the Class A Preferred Units should be reclassified from permanent to mezzanine equity. Additionally, the Company entered into the Second Amended and Restated Limited Liability Company Agreement in 2019, which provided the holders of Class A units an 8% per annum preferred return.  The Company determined that the amendment should be accounted for as a modification. Therefore, the Company recorded the incremental increase in fair value as an adjustment to the carrying value of Class A units with an offset to APIC equivalent and accumulated deficit.  

Capitated Revenues

Medicare pays capitation using a “risk adjustment model”, which compensates providers based on the health status (acuity) of each individual patient (via a Risk Adjustment Factor, “RAF”). The Company’s policy is to recognize the variable RAF component of capitation revenues, to the extent that it is probable a significant reversal will not occur.  At the December 31, 2020 balance sheet date the Company determined its estimates of the RAF components of certain capitation revenues were constrained and therefore not estimable, as it was not probable a significant reversal would not occur.  The Company subsequently collected the RAF components of capitation payments prior to the issuance of the 2020 financial statements, effectively relieving the constraints which previously existed at the December 31, 2020 balance sheet date. As a result, capitation revenues for 2020 were restated based on the results of management’s analysis of the RAF component of cash receipts collected prior to the issuance 2020 financial statements which were previously determined to not be estimable. The revenue now recognized in 2020 was previously recognized in June of 2021. The total amount of the RAF adjustment was $6,532,954.

There were two other errors related to capitated revenue, other patient service revenue, and medical expenses which were corrected in the restatement. Firstly, the Company has reclassified capitated revenue streams attributable to the Network. These capitated revenues were previously classified as “other patient service revenue” and then have been reclassified into “capitated revenue”. Secondly, the Company has eliminated intercompany revenue and expense related to transactions between Bacchus and P3-NV that should have been eliminated in consolidation. Prior to the restatement noted above regarding capitated revenue, this adjustment was a decrease to other patient service revenue and a decrease to medical expenses.

Disclosure Correction

The disclosure of the condensed financial statement of the Company’s consolidated VIE has been corrected for accrued interest and interest expense relating to the advances made to the VIE for the period ended March 31, 2021 (see Note 25).  There is no impact to the condensed consolidated financial statements of the Company of this correction to the disclosures.

7

Table of Contents

The following tables summarize the restatement adjustments on each financial statement line item affected by the restatement as of the dates, and for the periods, indicated:

As Previously

Network

Preferred Returns

Class A Units

Revenue

   

Reported

   

Adjustment

   

Adjustment

   

Adjustments

   

Adjustment

   

As Restated

Condensed Consolidated Statement of Operations for the Three Months Ended March 31, 2021 (Unaudited)

Capitated Revenue

$

147,700,465

$

$

$

$

1,263,725

$

148,964,190

Other Patient Service Revenue

3,863,915

(1,530,165)

2,333,750

Total Operating Revenue

151,564,380

(266,440)

151,297,940

Medical Expenses

146,890,945

(266,440)

146,624,505

Total Operating Expenses

164,552,810

(266,440)

164,286,370

Interest Expense, net

(4,081,134)

1,956,848

(2,124,286)

Total Other Expenses

(13,619,130)

1,956,848

(11,662,282)

Net Loss Attributable to Non-Controlling Interests

(3,282,292)

3,282,292

Net Loss (formerly Net Loss Attributable to Controlling Interests)

(23,325,268)

(3,282,292)

1,956,848

(24,650,712)

Condensed Consolidated Statements of Changes in Members’ Deficit for the 3 Months Ended March 31, 2021

Preferred Return at 8% for Class A Units

$

890,612

$

$

(890,612)

$

$

Net Loss

(26,607,560)

1,956,848

(24,650,712)

Balance as of March 31,2021

(122,918,168)

5,633,581

(43,656,269)

6,532,954

(154,407,902)

Condensed Consolidated Statements of Cash Flows for the 3 Months Ended March 31, 2021

Net Loss

$

(26,607,560)

$

$

1,956,848

$

(24,650,712)

Class A and Class D Preferred Returns

1,956,848

(1,956,848)

Consolidated Statements of Changes in Members’ Deficit for the Year Ended December 31, 2020

Balance as of December 31, 2020

$

(97,661,735)

$

$

4,567,346

$

(43,656,270)

$

6,532,954

$

(130,217,705)

*Rounding may cause variances

Note 3: Going Concern and Liquidity

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced losses since its inception and had losses of $60,790,254 for the three-month periods ended March 31, 2022, and $24,650,712 for the three-month periods ended March 31, 2021. Such losses were primarily the result of costs incurred in adding new members, building relationships with physician partners and payors, and developing new services. The Company anticipates operating losses and negative cash flows to continue for the foreseeable future as it continues to grow membership.

As of March 31, 2022, and December 31, 2021, the Company had $110,345,801 and $140,477,586, respectively, in unrestricted cash and cash equivalents available to fund future operations. The Company’s capital requirements will depend on many factors, including the pace of our growth, ability to manage medical costs, the maturity of our members, and our ability to raise capital, and the Company will need to use available capital resources and/or raise additional capital earlier than currently anticipated. When the Company pursues additional debt and/or equity financing, there can be no assurance that such financing will be available on terms commercially acceptable to the Company. If the Company is unable to obtain additional funding when needed, it will need to curtail planned activities

8

Table of Contents

in order to reduce costs, which will likely have an unfavorable effect on the Company’s ability to execute on its business plan, and have an adverse effect on its business, results of operations and future prospects. As a result of these matters, substantial doubt exists about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Note 4: Significant Accounting Policies

Principles of Consolidation

The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of the Company, and its subsidiaries, all of which are controlled by the Company through majority voting control, and variable interest entities for which the Company is the primary beneficiary. As more fully described in Note 25 “Variable Interest Entities”, the Company is the primary beneficiary of the following physician practices (“Network”):

Kahan, Wakefield, Abdou, PLLC (“KWA”)

Bacchus, Wakefield, Kahan, PC (“BACC”)

P3 Health Partners Professional Services PC

P3 Medical Group, P.C.

P3 Health Partners California, P.C.

All intercompany accounts and transactions have been eliminated in consolidation.

Variable Interest Entities (“VIE” or “VIEs”)

Management analyzes whether the Company has any financial interests in VIEs. This analysis includes a qualitative review based on an evaluation of the design of the entity, its organizational structure, including decision making ability and financial agreements, as well as a quantitative review. Accounting Standards Codification (“ASC”) Topic 810, Consolidation (“ASC 810”), requires a reporting entity to consolidate a VIE when that reporting entity has a variable interest that provides it with a controlling financial interest in the VIE. The entity which consolidates a VIE is referred to as the primary beneficiary of the VIE. See Note 25 “Variable Interest Entities”.

Segment Reporting

The Company presents the financial statements by segment in accordance with Accounting Standard Codification Topic No. 280, Segment Reporting (“ASC 280”) to provide investors with transparency into how the chief operating decision maker (“CODM”) manages the business. The Company determined the CODM is its Chief Executive Officer. The Company’s CODM manages the operations on a consolidated basis to make decisions about overall corporate resource allocation and to assess overall corporate profitability based on consolidated revenues and adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”), as defined in Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. The Company has one reportable segment.

Management’s Use of Estimates

Preparation of these condensed consolidated financial statements and accompanying footnotes, in conformity with U.S. GAAP, requires Management to make estimates and assumptions that could affect amounts reported here. Management bases its estimates on the best information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID 19. See Note 23 “Commitments and Contingencies” for further discussion on the impact of COVID-19.

The areas where significant estimates are used in these accompanying condensed consolidated financial statements include revenue recognition, the liability for unpaid claims, unit-based and share-based compensation, premium deficiency reserves (“PDR”), fair value and impairment recognition of long-lived assets (including intangible assets and goodwill), fair value of acquired assets and liabilities in Business Combinations, fair value of liability classified instruments and judgments related to deferred income taxes. Actual results could differ from those estimates.

9

Table of Contents

Earnings (Loss) per Share and Member Unit

Basic and diluted net loss per share attributable to common stockholders in the Successor Period is presented in conformity with the two-class method required for participating securities.

Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of Public Warrants, Private Placement Warrants, restricted shares and escrow shares.

As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.

The Company analyzed the calculation of net loss per member unit for the Predecessor Period and determined that it resulted in values that would not be meaningful to the users of these condensed consolidated financial statements. Therefore, net loss per member unit information has not been presented for the Predecessor Period.

Cash and Restricted Cash

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits at banks. Accounts at each institution are insured up to $250,000 by the Federal Deposit Insurance Corporation (“FDIC”). At March 31, 2022, and December 31, 2021, the Company maintained its cash in bank deposit accounts that, at times, may have exceeded FDIC insured limits. Management does not expect any losses to occur on such accounts.

At March 31, 2022, and December 31, 2021, the Company had unrestricted cash of $110,345,801 and $140,477,586, respectively, deposited at banking institutions which are subject to the FDIC insured limit.

Successor

    

March 31, 2022

    

December 31, 2021

Checking

$

110,345,801

$

140,477,586

Restricted

 

356,242

 

356,286

Total Cash Balances

$

110,702,043

$

140,833,872

Restricted Cash is that which is held for a specific purpose (such as payment of partner distributions and legal settlements) and is thus not available to the Company for immediate or general business use. Restricted Cash appears as a separate line item on the Company’s condensed consolidated balance sheets.

The following table provides a reconciliation of cash and restricted cash reported on the condensed consolidated balance sheet at March 31, 2021, that sum to the total of this item reported in the condensed consolidated statement of cash flows.

    

Predecessor

March 31, 2021

Unrestricted

$

22,341,413

Restricted

 

3,687,918

Total Cash Balances

$

26,029,331

10

Table of Contents

Revenue Recognition and Revenue Sources

The Company categorizes revenue based on various factors such as the nature of contracts and order to billing arrangements as follows:

Successor

Predecessor

 

Three Months

Three Months

Ended

 

Ended

March 31, 2021

 

Revenue Type

    

March 31, 2022

    

% of Total

  

  

(As Restated)

    

% of Total

 

Capitated Revenue

$

269,684,815

 

98.6

%  

$

148,964,190

 

98.5

%

Other Patient Service Revenue:

Clinical Fees & Insurance Revenue

 

1,882,254

 

0.7

%  

 

821,762

 

0.5

%

Care Coordination / Management Fees

 

1,921,105

 

0.7

%  

 

1,503,353

 

1.0

%

Incentive Fees

 

56,160

 

0.0

%  

 

8,635

 

0.0

%

Total Other Patient Service Revenue

 

3,859,519

 

1.4

%  

 

2,333,750

 

1.5

%

Total Revenue

$

273,544,334

 

100.0

%  

$

151,297,940

 

100.0

%

The following table depicts the health plans from which the Company has a concentration of revenue that is 10.0% or more:

Successor

Predecessor

 

Three Months

  

  

Three Months

 

Ended

Ended

 

Plan Name

    

March 31, 2022

    

% of Total

  

  

March 31, 2021

    

% of Total

 

Health Plan C

$

55,321,176

 

20.2

%  

$

19,280,237

 

12.7

%

Health Plan B

 

48,019,382

 

17.6

%  

 

33,952,002

 

22.5

%

Health Plan A

 

45,238,065

 

16.5

%  

 

43,254,924

 

28.6

%

Health Plan D

 

36,862,961

 

13.5

%  

 

27,694,259

 

18.3

%

All Other

 

88,102,750

 

32.2

%  

 

27,116,518

 

17.9

%

Total Revenue

$

273,544,334

 

100.0

%  

$

151,297,940

 

100.0

%

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that an entity’s performance obligation is complete, and revenue is earned, upon the transfer of a promise to deliver services to customers commensurate with consideration to which it would expect to be received in exchange for the actual delivery of those services. The terms of the contract and all relevant facts and circumstances should be considered when applying this guidance. This includes application of a practical expedient (a “portfolio approach”) to contracts with similar characteristics and circumstances. Specific revenue streams are described in more detail below.

Capitated Revenue

The Company contracts with health plans using an at-risk (shared savings) model. Under the at-risk model, the Company is responsible for the cost of all covered services provided to members assigned by the health plans to the Company in exchange for a fixed premium payment, which generally is a percentage of the payment based on health plans’ premiums received from CMS. Through this capitation arrangement, the Company stands ready to provide assigned Medicare Advantage beneficiaries all their medical care via the Company’s directly employed and affiliated physician/specialist network.

The premiums health plans receive are determined via a competitive bidding process with CMS and are based on the costs of care in local markets and the average utilization of services by patients enrolled. Medicare pays capitation using a “risk adjustment model”, which compensates providers based on the health status (acuity) of each individual patient. Medicare Advantage plans with higher acuity patients receive higher premiums. Conversely, Medicare Advantage plans with lower acuity patients receive lesser premiums. Under the risk adjustment model, capitation is paid on an interim basis based on enrollee data submitted for the preceding year and is adjusted in subsequent periods after final data is compiled. The Company generally estimates transaction prices using the most likely methodology. Amounts are only included in the transaction price to the extent any significant uncertainty of reversal on cumulative revenue will not occur and is, furthermore, resolved. In certain contracts, PMPM fees also include adjustments for items such as performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors.

11

Table of Contents

Capitated revenues are recognized based on an estimated PMPM transaction price to transfer the service for a distinct increment of the series (e.g., month) and is recognized net of projected acuity adjustments and performance incentives or penalties as Management cannot reasonably estimate the ultimate PMPM payment of those contracts. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term. The capitation amount is subject to possible retroactive premium risk adjustments based on the member’s individual acuity. There were no premium risk adjustments recorded in 2021 or the first quarter of 2022 as related to prior years. As the period between the time of service and time of payment is typically one year or less, Management elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.

The Company’s contracts with health plans may include core functions and services for managing assigned patients’ medical care. The combination of those services is offered as one “single solution” (“bundle”). Capitation contracts have a single performance obligation that is a stand ready obligation to perform healthcare services to the population of enrolled members and constitutes a series for the provision of managed healthcare services for the term of the contract, which is deemed to be one month since the mix of patients-customers can change month over month. The Company does not offer nor price each individual function as a standalone a la carte service to health plans. However, the addition or exclusion of certain services may be negotiated and reflected in each health plan’s specific total percent of the premium (“POP”).

At March 31, 2022, and December 31, 2021, the Company had POP contracts in effect with 20 health plans (across 5 states) and 17 health plans (across 4 states), respectively.

Each month, in accordance with contractual obligations (for non-delegated health plans; e.g. – those for which the Company has not been delegated for claims processing), each plan funds a medical claims payment reserve equal to a defined percentage of premium attributable to members assigned to the Company. In turn, the Company administers and funds medical claims for contractually covered services, for assigned health plan members, from that health plan’s reserve. On a quarterly or monthly basis, health plans conduct a settlement of the reserve to determine any surplus or deficit amount. The reconciliation and distribution of the reserve occur within 120 days following the end of each quarter. An annual settlement reconciliation and distribution from all funds occurs within twenty-one months following each year-end.

At March 31, 2022, and December 31, 2021, health plan receivables and health plan settlement payables, by health plan, by year, were as follows:

Health Plan Receivables

Successor

    

March 31, 2022

    

December 31, 2021

Health Plan A

$

11,959,398

$

4,695,712

Health Plan B

 

25,363,650

 

15,473,828

Health Plan C

 

21,171,875

 

1,380,752

Health Plan D

 

5,403,444

 

6,651,586

Health Plan E

 

1,925,609

 

2,439,046

Health Plan F

 

2,481,449

 

2,925,751

Health Plan G

 

4,810

 

239,375

Health Plan H

 

5,393,408

 

2,185,619

Health Plan I

 

1,195,066

 

1,134,750

Health Plan J

 

(76,957)

 

149,915

Health Plan K

 

3,458,907

 

2,705,147

Health Plan L

 

1,086,891

 

899,560

Health Plan M

 

3,079,579

 

1,747,116

Health Plan N

 

1,380,499

 

974,092

Health Plan O

 

2,799,215

 

666,291

Health Plan P

 

343,015

 

106,162

Health Plan Q

 

209,930

 

61,990

Health Plan R

 

4,008,617

 

3,578,682

Health Plan S

 

289,045